research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Over longer periods, or populations at high risk of obesity, GLP-1 receptor agonists may have a more favorable cost-effectiveness analysis. Despite the economic considerations, GLP-1 receptor agonists are included in clinical guidelines for obesity management due to their demonstrated efficacy in weight loss and cardiometabolic risk improvement. The high cost has been identified and is seen as a barrier to access and widespread use in many healthcare systems.
== Classification == Epidermolysis bullosa refers to a group of disorders that involve the formation of blisters following trivial trauma. Over 300 mutations have been identified in this condition. They have been classified into the following types:
== Medical uses == In the US, gabapentin is indicated for the treatment of postherpetic neuralgia and as an adjunctive therapy in the treatment of partial-onset seizures without secondary generalization in people with epilepsy. Gabapentin is recommended for use in focal seizures and neuropathic pain. Gabapentin is prescribed off-label in the US and the UK, for example, for the treatment of non-neuropathic pain, anxiety disorders, sleep problems and bipolar disorder. In recent years, gabapentin has seen increased use, particularly in the elderly. There is concern regarding gabapentin's off-label use due to the lack of strong scientific evidence for its efficacy in multiple conditions, its proven side effects and its potential for misuse and physical/psychological dependency. Some harms, including nervous system harms, have been underreported in published trials of gabapentin, potentially resulting in the underestimation of harms in guidelines for the use of gabapentin.
On 3 January 2022, Hangman's Chair appeared on the Culturebox program on France 4. A Loner was released in February 2022. The band released the single "Who Wants To Die Old" alongside a music video directed by Oscar Bizarre, filmed before "Cold & Distant". A piece was finally performed by the pairing of Hangman's Chair and Regarde Les Hommes Tomber at the Roadburn Festival 2022 in Tilburg, Netherlands. On 23 June 2022, Arte Concert and Rolling Stone France teamed up to broadcast live the band's performance at Hellfest on YouTube. On 26 June, Hangman's Chair collaborated once again with the Nantes-based band Regarde Les Hommes Tomber for a concert on the Valley stage at Hellfest. The band performed at Les Francofolies in La Rochelle, France, and at other music festivals, and toured for five weeks with Paradise Lost. Hangman's Chair were ranked first in the "Best French Bands/Artists" category on the editorial board's year-end list of Guitar Part, a French monthly print magazine aimed at guitarists. Before embarking on a European tour with Igorrr, they presented a previously unreleased track, the six-minute single "Spleenwise", in March 2023. In 2023, Hangman's Chair were encouraged by their label to release a short, three-minute documentary titled A Portrait, directed by Kendy Ty, in which the band members recount their career and the A Loner era in a condensed and introspective way. For the documentary, the musicians returned to their neighbourhood, the school, and the playground where they grew up. In July 2023, the band performed at the Dour Festival in Belgium.
Sources: en.wikipedia.org
=== Category:EC 1.12 (act on hydrogen as a donor) === Category:EC 1.12.1 (with NAD+ or NADP+ as acceptor) Category:EC 1.12.2 (with a cytochrome as acceptor) Category:EC 1.12.5 (with a quinone or similar compound as acceptor) Category:EC 1.12.7 (with an iron–sulfur protein as acceptor) Category:EC 1.12.98 (with other known acceptors) Category:EC 1.12.99 (with other acceptors)
==== Reactions and political crisis ==== However, rather than address concerns, Héctor Valer's nomination amplified the political crisis. On 3 February 2022, it was revealed that Valer had been the subject of two complaints of violence by his wife and daughter in 2016, over which a court had granted him protection in 2017. In a press conference, Valer denied the allegations alleging lack of evidence or convictions, and defended himself by saying he had only "reprimanded" his daughter without violence. Later the same night, all parliamentary groups (i.e., FP, AP, AvP, RP and PP, except SP whose group is divided between support and distrust) officially condemned the acts committed and announced that they would not grant a vote of confidence to the Valer. The following day, 4 February 2022, the ruling party Free Peru decided after not to grant a vote of confidence to Valer. A few hours later, the four members of the Together for Peru group, with the exception of the minister and deputy Roberto Sánchez, also decided not to grant the vote of confidence. Despite the extent of the political crisis, Héctor Valer announced at 11:00am on 4 February 2022 that he would attend Congress the following day to request a vote of confidence. In reaction, the President of Congress Maricarmen Alva rejected the possibility of a vote of confidence the following day.
== Antibacterial activity == Lariocidin exhibits broad-spectrum antimicrobial activity in vitro against a range of clinically relevant bacteria, including Gram-positive (Staphylococcus aureus), Gram-negative (Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli), and mycobacteria. Lariocidin is efficient in nutrient-limited conditions that are reflective of the host environment bacteria encounter during an infection and active against strains resistant to many existing antibiotic classes. In mouse infection experiments, lariocidin demonstrated efficacy in a neutropenic thigh model of multidrug-resistant A. baumannii infection, with significant reduction of bacterial burden compared with controls. The initial preclinical data indicated a favorable therapeutic window and no observed cytotoxicity in human cell assays, supporting further investigation as a lead compound.
About 99% of the mass of the human body is made up of six elements: oxygen, carbon, hydrogen, nitrogen, calcium, and phosphorus. Only about 0.85% is composed of another five elements: potassium, sulfur, sodium, chlorine, and magnesium. All 11 are necessary for life. The remaining elements are trace elements, of which more than a dozen are thought on the basis of good evidence to be necessary for life. All of the mass of the trace elements put together (less than 10 grams for a human body) do not add up to the body mass of magnesium, the least common of the 11 non-trace elements.
=== Syndesmotic tear === The severity of acute syndesmosis injury is rated from grade I to III by several authors. A grade I injury is a partial anteroinferior tibiofibular ligament tear, meaning the exorotation and squeeze tests are negative for this grade. Grade II injury is a complete anteroinferior tibiofibular ligament and inferior interosseous ligament tear, meaning that squeeze test and exorotation are positive. This results in the injury being stabilized with immobilization but not operatively stabilized. A grade III injury is a complete anteroinferior tibiofibular ligament tear including a (partial) interosseous ligament tear and deltoid ligament avulsion, meaning the joint is unstable and positive on the exorotation and squeeze tests. This grade requires operative stabilization. If the syndesmosis is torn apart as result of bone fracture, surgeons will sometimes fix the relevant bones together with a syndesmotic screw, temporarily replacing the syndesmosis, or with a tightrope fixation, which is called syndesmosis procedure. The screw inhibits normal movement of the bones and, thereby, the corresponding joint(s). When the natural articulation is healed, the screw may be removed. The tightrope fixation with elastic fiberwire suture on the other hand allows physiologic motion of the ankle and may be permanent.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.